Search Results - "Cooper, J Mark"

Refine Results
  1. 1

    Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells by McNeill, Alisdair, Magalhaes, Joana, Shen, Chengguo, Chau, Kai-Yin, Hughes, Derralyn, Mehta, Atul, Foltynie, Tom, Cooper, J. Mark, Abramov, Andrey Y., Gegg, Matthew, Schapira, Anthony H.V.

    Published in Brain (London, England : 1878) (01-05-2014)
    “…Heterozygous GBA gene mutations are the most frequent Parkinson’s disease risk factor. Using Parkinson’s disease patient derived fibroblasts McNeill et al…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy by Gegg, Matthew E., Cooper, J. Mark, Chau, Kai-Yin, Rojo, Manuel, Schapira, Anthony H.V., Taanman, Jan-Willem

    Published in Human molecular genetics (15-12-2010)
    “…Mitochondrial dysfunction and perturbed degradation of proteins have been implicated in Parkinson's disease (PD) pathogenesis. Mutations in the Parkin and…”
    Get full text
    Journal Article
  4. 4

    Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission by Alvarez-Erviti, Lydia, Seow, Yiqi, Schapira, Anthony H, Gardiner, Chris, Sargent, Ian L, Wood, Matthew J.A, Cooper, J. Mark

    Published in Neurobiology of disease (01-06-2011)
    “…Abstract Alpha-synuclein aggregation plays a central role in Parkinson's disease pathology. Direct transmission of alpha-synuclein from pathologically affected…”
    Get full text
    Journal Article
  5. 5

    Glial activation precedes alpha-synuclein pathology in a mouse model of Parkinson’s disease by Izco, Maria, Blesa, Javier, Verona, Guglielmo, Cooper, J Mark, Alvarez-Erviti, Lydia

    Published in Neuroscience research (01-09-2021)
    “…[Display omitted] •Microglial cell activation in SNpc precedes alpha-synuclein inclusion formation.•In striatum a significant astrogliosis was observed 90…”
    Get full text
    Journal Article
  6. 6

    Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains by Gegg, Matthew E., Burke, Derek, Heales, Simon J. R., Cooper, J. Mark, Hardy, John, Wood, Nicholas W., Schapira, Anthony H. V.

    Published in Annals of neurology (01-09-2012)
    “…Objective: Mutations in the glucocerebrosidase gene (GBA) represent a significant risk factor for developing Parkinson disease (PD). We investigated the…”
    Get full text
    Journal Article
  7. 7

    Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage by Cleeter, Michael W.J., Chau, Kai-Yin, Gluck, Caroline, Mehta, Atul, Hughes, Derralynn A., Duchen, Michael, Wood, Nicholas William, Hardy, John, Mark Cooper, J., Schapira, Anthony Henry

    Published in Neurochemistry international (01-01-2013)
    “…► Glucocerebrosidase gene mutations are a risk factor for Parkinson’s disease. ► Glucocerebrosidase inhibition causes mitochondrial dysfunction & oxidative…”
    Get full text
    Journal Article
  8. 8

    G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization by PAPKOVSKAIA, Tatiana D, CHAU, Kai-Yin, MARK COOPER, J, INESTA-VAQUERA, Francisco, PAPKOVSKY, Dmitri B, HEALY, Daniel G, NISHIO, Koji, STADDON, James, DUCHEN, Michael R, HARDY, John, SCHAPIRA, Anthony H. V

    Published in Human molecular genetics (01-10-2012)
    “…The G2019S leucine rich repeat kinase 2 (LRRK2) mutation is the most common genetic cause of Parkinson's disease (PD), clinically and pathologically…”
    Get full text
    Journal Article
  9. 9

    Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells by Gegg, Matthew E, Cooper, J Mark, Schapira, Anthony H V, Taanman, Jan-Willem

    Published in PloS one (09-03-2009)
    “…Mitochondrial dysfunction has been implicated in the pathogenesis of Parkinson's disease (PD). Impairment of the mitochondrial electron transport chain (ETC)…”
    Get full text
    Journal Article
  10. 10

    Intranasal Delivery of pGDNF DNA Nanoparticles Provides Neuroprotection in the Rat 6-Hydroxydopamine Model of Parkinson’s Disease by Aly, Amirah E.-E., Harmon, Brendan T., Padegimas, Linas, Sesenoglu-Laird, Ozge, Cooper, Mark J., Waszczak, Barbara L.

    Published in Molecular neurobiology (01-01-2019)
    “…Glial cell line-derived neurotrophic factor (GDNF) gene therapy could offer a disease-modifying treatment for Parkinson’s disease (PD). Here, we report that…”
    Get full text
    Journal Article
  11. 11
  12. 12

    Efficient non-viral ocular gene transfer with compacted DNA nanoparticles by Farjo, Rafal, Skaggs, Jeff, Quiambao, Alexander B, Cooper, Mark J, Naash, Muna I

    Published in PloS one (20-12-2006)
    “…The eye is an excellent candidate for gene therapy as it is immune privileged and much of the disease-causing genetics are well understood. Towards this goal,…”
    Get full text
    Journal Article
  13. 13

    Intranasal delivery of hGDNF plasmid DNA nanoparticles results in long-term and widespread transfection of perivascular cells in rat brain by Aly, Amirah E-E., Harmon, Brendan, Padegimas, Linas, Sesenoglu-Laird, Ozge, Cooper, Mark J., Yurek, David M., Waszczak, Barbara L.

    Published in Nanomedicine (01-02-2019)
    “…The intranasal route of administration allows large therapeutics to circumvent the blood–brain barrier and be delivered directly to the CNS. Here we examined…”
    Get full text
    Journal Article
  14. 14

    Comparative analysis of DNA nanoparticles and AAVs for ocular gene delivery by Han, Zongchao, Conley, Shannon M, Makkia, Rasha, Guo, Junjing, Cooper, Mark J, Naash, Muna I

    Published in PloS one (18-12-2012)
    “…Gene therapy is a critical tool for the treatment of monogenic retinal diseases. However, the limited vector capacity of the current benchmark delivery…”
    Get full text
    Journal Article
  15. 15

    Cell Surface Nucleolin Serves as Receptor for DNA Nanoparticles Composed of Pegylated Polylysine and DNA by Chen, Xuguang, Kube, Dianne M, Cooper, Mark J, Davis, Pamela B

    Published in Molecular therapy (01-02-2008)
    “…Compacted DNA nanoparticles deliver transgenes efficiently to the lung following intrapulmonary dosing. Here we show that nucleolin, a protein known to shuttle…”
    Get full text
    Journal Article
  16. 16
  17. 17

    A partial structural and functional rescue of a retinitis pigmentosa model with compacted DNA nanoparticles by Cai, Xue, Nash, Zack, Conley, Shannon M, Fliesler, Steven J, Cooper, Mark J, Naash, Muna I

    Published in PloS one (24-04-2009)
    “…Previously we have shown that compacted DNA nanoparticles can drive high levels of transgene expression after subretinal injection in the mouse eye. Here we…”
    Get full text
    Journal Article
  18. 18
  19. 19

    Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson’s disease pathogenesis by Chau, Kai‐Yin, Ching, Hey Long, Schapira, Anthony H. V., Cooper, J. Mark

    Published in Journal of neurochemistry (01-08-2009)
    “…Alpha synuclein can be phosphorylated at serine129 (P‐S129), and the presence of highly phosphorylated α‐synuclein in Lewy bodies suggests changes to its…”
    Get full text
    Journal Article
  20. 20

    Enhancement of airway gene transfer by DNA nanoparticles using a pH-responsive block copolymer of polyethylene glycol and poly- l -lysine by Boylan, Nicholas J, Kim, Anthony J, Suk, Jung Soo, Adstamongkonkul, Pichet, Simons, Brian W, Lai, Samuel K, Cooper, Mark J, Hanes, Justin

    Published in Biomaterials (01-03-2012)
    “…Abstract Highly compacted DNA nanoparticles, composed of single molecules of plasmid DNA compacted with block copolymers of polyethylene glycol and poly- l…”
    Get full text
    Journal Article